MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026
Rhea-AI Summary
MaxCyte (NASDAQ: MXCT) will release its second quarter 2026 financial results after the U.S. market close on Wednesday, August 12, 2026. Company management will host an earnings conference call at 4:30 p.m. Eastern Time, with live and archived webcast access via the Events section of its investor website.
Positive
- None.
Negative
- None.
Market reaction after 2Q26 earnings date: MXCT -4.93% in the Jul 16 session
In the Jul 16 session, MXCT declined 4.93%, reflecting a moderate negative market reaction. Argus tracked a trough of -12.2% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 29 | Earnings date notice | Neutral | +7.6% | Announced Q1 2026 results date and post-close conference call registration details. |
| Feb 23 | Earnings date notice | Neutral | +5.0% | Set Q4 and FY2025 results release date and 4:30 p.m. ET earnings call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent earnings date notices have coincided with consistently positive next-day share moves for MaxCyte.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, Md., July 15, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the second quarter 2026 after the U.S. market close on Wednesday, August 12th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.
Earnings Conference Call Details
Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/.
About MaxCyte
At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure™ gene editing risk assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we’ve been advancing cell engineering, shaping the future of medicine.
Learn more at maxcyte.com and follow us on LinkedIn and Bluesky.
Investor Relations
Gilmartin Group
Erik Abdow
ir@maxcyte.com
Media Relations
Oak Street Communications
Kristen White
+1 415-608-6060
kristen@oakstreetcommunications.com
